Analyst Charles Zhu of LifeSci Capital maintained a Buy rating on Crescent Biopharma, retaining the price target of $22.00.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Charles Zhu has given his Buy rating due to a combination of factors that highlight Crescent Biopharma’s promising pipeline and strategic positioning in the oncology market. The company is on track with its investigational new drug (IND) submissions for CR-001 and CR-002, which are expected to be significant contributors to its growth. CR-001, a PD-1 x VEGF bispecific, has shown cooperative pharmacology in preclinical studies, enhancing T-cell activation and potentially offering a competitive edge similar to ivonescimab.
Additionally, Crescent Biopharma’s management has expressed confidence in their operational readiness and the positive reception from investigators globally, which bodes well for future clinical trials. The company’s engagement with multiple global sites and the enthusiasm for their PD-1 x VEGF class further support the potential for success. With a robust cash position and strategic development plans, Crescent Biopharma is well-positioned to capitalize on opportunities in the fragmented oncology market, justifying the Buy rating.